TY - JOUR
T1 - Gender-specific 11-dehydro-thromboxane B2 levels in acute coronary syndrome and its association with clinical outcomes
AU - Chauhan, Sheetal
AU - Singh, Ajit
AU - Karkala, Yeshwanth Rao
AU - Devasia, Tom
AU - Kareem, Hashir
AU - Uppunda, Deepak
AU - Shetty, Prasad Narayana
AU - Paramasivam, Ganesh
N1 - Funding Information:
Dr. Tom Devasia has received research grants from Novartis, India. Dr. Ajit Singh and Dr. Ganesh Paramasivam are working as co-investigator in clinical trials funded by Novartis, India. All the above-mentioned declarations have no impact on the
Publisher Copyright:
© 2020 © 2020 Sheetal Chauhan et al. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - Despite knowing that females are at a higher risk of major adverse cardiac events (MACE) and poor prognosis after percutaneous transluminal coronary angioplasty (PTCA), there are very few studies focusing on urinary 11-dehyrdothromboxane B2 (dh-TxB2) concentration (for aspirin non-responsiveness) differences among males and females. The present prospective observational study aimed to evaluate the dh-TxB2 levels and associate them with clinical outcomes in males and females with acute coronary syndrome (ACS) after PTCA. The dh-TxB2 ELISA assay was carried out twice, at baseline and 6 months follow-up, and outcomes were assessed for 1 year. The average cut-off value of dh-TxB2 was ≥1,496 pg/mg creatinine by the receiver operating characteristic curve estimation. A total of 192 patients (140 men and 52 women) were enrolled. At baseline, 17 (12.1%) males and 7 (13.5%) females had high dh-TxB2 levels, whereas at 6 months, 22 (15.9%) males and 4 (7.8%) females showed high dh-TxB2 levels. The concentration of dh-TxB2 was higher in females than males at baseline. Composite MACE was not different between genders significantly even when the dh-TxB2 levels were high. Women experienced higher MACE incidences than men (13.5%vs. 9.3%).
AB - Despite knowing that females are at a higher risk of major adverse cardiac events (MACE) and poor prognosis after percutaneous transluminal coronary angioplasty (PTCA), there are very few studies focusing on urinary 11-dehyrdothromboxane B2 (dh-TxB2) concentration (for aspirin non-responsiveness) differences among males and females. The present prospective observational study aimed to evaluate the dh-TxB2 levels and associate them with clinical outcomes in males and females with acute coronary syndrome (ACS) after PTCA. The dh-TxB2 ELISA assay was carried out twice, at baseline and 6 months follow-up, and outcomes were assessed for 1 year. The average cut-off value of dh-TxB2 was ≥1,496 pg/mg creatinine by the receiver operating characteristic curve estimation. A total of 192 patients (140 men and 52 women) were enrolled. At baseline, 17 (12.1%) males and 7 (13.5%) females had high dh-TxB2 levels, whereas at 6 months, 22 (15.9%) males and 4 (7.8%) females showed high dh-TxB2 levels. The concentration of dh-TxB2 was higher in females than males at baseline. Composite MACE was not different between genders significantly even when the dh-TxB2 levels were high. Women experienced higher MACE incidences than men (13.5%vs. 9.3%).
UR - http://www.scopus.com/inward/record.url?scp=85096652915&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096652915&partnerID=8YFLogxK
U2 - 10.7324/JAPS.2020.10112
DO - 10.7324/JAPS.2020.10112
M3 - Article
AN - SCOPUS:85096652915
SN - 2231-3354
VL - 10
SP - 10
EP - 17
JO - Journal of Applied Pharmaceutical Science
JF - Journal of Applied Pharmaceutical Science
IS - 11
ER -